Almatica Drug Patent Portfolio
Almatica owns 3 orange book drugs protected by 12 US patents Given below is the list of Almatica's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8999393 | Sustained release formulations of lorazepam | 08 Jan, 2034 | Active |
| US7776358 | Extended release venlafaxine besylate tablets | 16 May, 2028 | Active |
| US7438927 | Methods of treatment using a gastric retained gabapentin dosage | 26 Feb, 2024 | Expired |
| US6717015 | Venlafaxine besylate | 27 Mar, 2023 | Expired |
| US7731989 | Gastric retained gabapentin dosage form | 25 Oct, 2022 | Expired |
| US8192756 | Gastric retained gabapentin dosage form | 25 Oct, 2022 | Expired |
| US8252332 | Gastric retained gabapentin dosage form | 25 Oct, 2022 | Expired |
| US8333992 | Gastric retained gabapentin dosage form | 25 Oct, 2022 | Expired |
| US6723340 | Optimal polymer mixtures for gastric retentive tablets | 25 Oct, 2021 | Expired |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms | 20 Jun, 2020 | Expired |
| US6340475 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
| US6635280 | Extending the duration of drug release within the stomach during the fed mode | 19 Sep, 2016 | Expired |
Latest Legal Activities on Almatica's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Almatica.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 08 Jul, 2024 | US8192756 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US8252332 |
|
Maintenance Fee Reminder Mailed
Critical
| 22 Jan, 2024 | US8192756 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Sep, 2022 | US8999393 |
|
Expire Patent
Critical
| 11 Jul, 2022 | US7731989 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 02 Feb, 2022 | US7776358 |
|
Maintenance Fee Reminder Mailed
Critical
| 24 Jan, 2022 | US7731989 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Jun, 2020 | US8333992 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2020 | US7438927 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2020 | US8252332 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Dec, 2019 | US8192756 |
| Mail O.P. Petition Decision | 25 Jun, 2019 | US8999393 |
|
Email Notification
Critical
| 25 Jun, 2019 | US8999393 |
|
Mail-Petition Decision - Dismissed
Critical
| 21 Jun, 2019 | US8999393 |
| O.P. Petition Decision | 20 Jun, 2019 | US8999393 |
Almatica's Drug Patent Litigations
Almatica's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 31, 2008, against patent number US7776358. The petitioner , challenged the validity of this patent, with Joan Cucala Escoi et al as the respondent. Click below to track the latest information on how companies are challenging Almatica's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6340475 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Final Written Decision
(21 Sep, 2015)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6723340 | April, 2014 |
Final Written Decision
(16 Sep, 2015)
| DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6340475 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| Depomed, Inc. | Purdue Pharma L.P. |
| US6635280 | January, 2014 |
FWD Entered
(08 Jul, 2015)
| DepoMed, Inc. | Purdue Pharma L.P. |
| US6340475 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6635280 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| Depomed, Inc. | Endo Pharmaceutical Inc. et al. |
| US6723340 | April, 2014 |
Institution Denied
(29 Sep, 2014)
| DepoMed, Inc. | Endo Pharmaceutical Inc. et al. |
| US7776358 | December, 2008 |
Decision
(13 Feb, 2010)
| Joan Cucala Escoi et al | |
Almatica Drug Patents' Oppositions Filed in EPO
Almatica drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 03, 2014, by Purdue Pharma Lp. This opposition was filed on patent number EP02781665A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP02781665A | Jan, 2014 | Purdue Pharma LP | Patent maintained as amended |
Almatica's Family Patents
Almatica Drug List
Given below is the complete list of Almatica's drugs and the patents protecting them.
1. Gralise
Gralise is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7438927 | Methods of treatment using a gastric retained gabapentin dosage |
26 Feb, 2024
(7 months ago)
| Expired |
| US7731989 | Gastric retained gabapentin dosage form |
25 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US8192756 | Gastric retained gabapentin dosage form |
25 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US8252332 | Gastric retained gabapentin dosage form |
25 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US8333992 | Gastric retained gabapentin dosage form |
25 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US6723340 | Optimal polymer mixtures for gastric retentive tablets |
25 Oct, 2021
(2 years ago)
| Expired |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
| US6340475 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
| US6635280 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gralise's drug page
2. Loreev Xr
Loreev Xr is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8999393 | Sustained release formulations of lorazepam |
08 Jan, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Loreev Xr's drug page
3. Venlafaxine Besylate
Venlafaxine Besylate is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7776358 | Extended release venlafaxine besylate tablets |
16 May, 2028
(3 years from now)
| Active |
| US6717015 | Venlafaxine besylate |
27 Mar, 2023
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Venlafaxine Besylate's drug page